The annual meeting of the American Urological Association (AUA) was held May 3-6 in Chicago. Fourteen scientific abstracts featured high-intensity focused ultrasound (HIFU) technology for prostate and kidney applications, with many studies comparing HIFU to other treatment options. One significant highlight was Profound Medical’s presentation of the final data from their TULSA-PRO Ablation Clinical Trial (TACT).
“The interest and attention to ultrasound ablation technologies at this year’s AUA was impressive. Compared to previous meetings, there was a near-exponential increase in attendance, debate, and enthusiasm for incision-free prostate ablation treatments,” said Mathieu Burtnyk, VP Clinical Affairs at Profound Medical. “We were particularly delighted to have the outcomes of our TACT Pivotal Study, designed for registration with the US FDA, presented during the Next Frontier plenary session by Dr. Scott Eggener, Director of the Prostate Cancer Program at University of Chicago Medicine. The response from the clinical community has been very positive, both from physicians who value customized whole-gland treatments, as well as those excited to offer predictable targeted prostate ablations in their practice.”
Focused ultrasound-related abstracts are listed below. The full text for each abstract can be found online in Volume 201, Supplement 4, of the Journal of Urology, published April 1, 2019.
MP33-08 PROSTATE CANCER TREATMENT OPTIONS: A CONTEMPORARY WORLDWIDE TREND ANALYSIS
MP67-19 URETHRAL STRICTURE AFTER HIGH-INTENSITY FOCUSED ULTRASOUND
MP78-08 PREDICTIVE FACTORS OF FAILURE FOLLOWING FOCAL THERAPY FOR PROSTATE CANCER
MP78-15 CONCOMITANT FOCAL THERAPY AND ROBOTIC LYMPHADENECTOMY IN PROSTATE CANCER: INITIAL SERIES
PD26-07 HOW DO ULTRASOUND WAVES CAUSE STONE FRACTURE IN BURST WAVE LITHOTRIPSY?
V05-05 MINIMALLY INVASIVE MANAGEMENT OF RECTOURETHRAL FISTULAS